| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000037156 |
| Receipt No. | R000042342 |
| Scientific Title | Safety and efficacy of thin bronchoscopic cryobiopsy through a long nasobronchial tube for lung diseases |
| Date of disclosure of the study information | 2019/06/24 |
| Last modified on | 2021/10/21 (Ver. 5) |
| Basic information | ||
| Public title | Safety and efficacy of thin bronchoscopic cryobiopsy through a long nasobronchial tube for lung diseases | |
| Acronym | Cryobiopsy through a nasobronchial tube | |
| Scientific Title | Safety and efficacy of thin bronchoscopic cryobiopsy through a long nasobronchial tube for lung diseases | |
| Scientific Title:Acronym | Cryobiopsy through a nasobronchial tube | |
| Region |
|
|
| Condition | |||
| Condition | Lung diseases | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the safety and efficacy of thin bronchoscopic cryobiopsy through a long nasobronchial tube for lung diseases |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1. Safety (frequency of bleeding) |
| Key secondary outcomes | 1. Safety (frequency of complications other than bleeding)
2. Pathological diagnostic yield 3. Procedural duration 4. Frequency of oxygen desaturation 5. Size of specimens |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with lung lesions on chest CT, to whom tissue sampling by cryobiopsy is considered adequate for a pathological diagnosis.
2. >=20 years old 3. Patients who can temporarily interrupt anticoagulant/antiplatelet agents 4. Informed consent |
|||
| Key exclusion criteria | 1. Lesion located within the inner second ellipse from the hilum on chest CT
2. Patients who were previously enrolled in this trial 3. Patients who need to undergo a bronchoscopic procedure for a nontarget lesion in the same setting 4. Patients with large lung cysts near the biopsy site 5. Lesions near a large vessel 6. Lesions inaccessible to the cryoprobe (e.g. apical lung lesions) 7. Patients with a diffuse lung disease who are receiving steroid therapy 8. Pregnant woman 9. Bleeding tendency 10. Pulmonary hypertension 11. Serious concomitant medical illness 12. Other clinical difficulties |
|||
| Target sample size | 80 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Hospital Organization Nagoya Medical Center | ||||||
| Division name | Department of Respiratory Medicine | ||||||
| Zip code | 460-0001 | ||||||
| Address | 4-1-1 Sannomaru, Naka-ku, Nagoya 460-0001, Japan | ||||||
| TEL | 052-951-1111 | ||||||
| masahideo@gmail.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | National Hospital Organization Nagoya Medical Center | ||||||
| Division name | Department of Respiratory Medicine | ||||||
| Zip code | 460-0001 | ||||||
| Address | 4-1-1 Sannomaru, Naka-ku, Nagoya 460-0001, Japan | ||||||
| TEL | 052-951-1111 | ||||||
| Homepage URL | |||||||
| masahideo@gmail.com | |||||||
| Sponsor | |
| Institute | National Hospital Organization Nagoya Medical Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The institutional review board of Nagoya Medical Center |
| Address | 4-1-1 Sannomaru, Naka-ku, Nagoya 460-0001, Japan |
| Tel | 052-951-1111 |
| 311-rec@mail.hosp.go.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Prospective observational study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042342 |